Abstract
Molecular mechanisms behind the defects in insulin production and secretion associated with antihuman immunodeficiency virus (anti-HIV) therapy and the development of HIV-associated lipodystrophy syndrome (HALS) are discussed in this article. Data suggesting insulin resistance on the beta cell and defects in first-phase insulin release of HALS patients are presented. Hepatic extraction of insulin, nonglucose insulin secretagogues and insulin-like growth factor release may exert influence on the demand of circulating insulin and on insulin secretion in HIV-infected patients. Finally, the paucity in understanding the incretin effects in HIV and HIV therapy in relation to insulin secretion is highlighted.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Endocrinology & Metabolism Clinics of North America |
Vol/bind | 43 |
Udgave nummer | 3 |
Sider (fra-til) | 697-708 |
Antal sider | 12 |
ISSN | 0889-8529 |
DOI | |
Status | Udgivet - sep. 2014 |